This week's BioPharma Dive brought to you by

The pharmaceutical system is at an inflection point: High costs, unclear pricing, and fragmented care are barriers for all stakeholders.

The access system needs to be rewired—it should be streamlined, with drug value measured by outcomes and affordability. We are in a unique position to do so. Read the article. Read our CEO’s new call to action!

Learn how a direct-to-payer model, alongside traditional PBM and direct-to-patient channels, creates a consistent, transparent, and reliable way for therapies to reach patients and ultimately lower today’s 30-50% abandonment rate.

In this quick read, discover how EVERSANA DIRECT is leading the shift in enabling pharma manufacturers to increase access, improve gross-to-net, and accelerate pull-through.

READ ARTICLE

	7045 College Boulevard, Suite 300, Overland Park, KS 66211
	©2025 EVERSANA. All Rights Reserved.

Want to reach 108,000+ biopharma executives with your own message? Get the media kit or contact us directly at advertising@industrydive.com.

About this email: You are receiving this message as part of your complimentary newsletter subscription to BioPharma Dive. If you no longer wish to receive the daily newsletter, you can switch to a weekly subscription or unsubscribe. See our full privacy policy. BioPharma Dive is a product of TechTarget, Inc. and its subsidiaries, 275 Grove St. Newton, MA, 02466